Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Drug Manufacturers - Specialty & Generic

Healthcare
$25.93 -0.71%

-$0.24 today

Market cap
$805.79M
Beta
0.75
P/E (TTM)
14.3
EPS (TTM)
$2.34
52W Low $29.19High $50.79

Volume 0.49M

Average 0.50M

COLL Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Collegium Pharmaceutical, Inc.NASDAQ: COLL

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns negative

Q1 FY2026 accounts payables was -$3.83M, compared with $13.92M a year earlier. Trailing-twelve-month accounts payables was -$11.03M.

Context

  • Accounts payables amounted to 0.9% of revenue in FY2025, down 0.9 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near -$3.83M or moves back toward the trailing-twelve-month quarterly average of -$2.76M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.83M-225.7% QoQ
Last fiscal yearDec 2025
$6.72M+159.6% YoY
LTMMar 2026
-$11.03M-313.0% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-127.5%——
1 year+159.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
6.72M USD
Year-over-year change
+159.6%

Accounts Payables vs competitors

How COLL compares with its peers on the latest reported figures

  • COLL's LTM Mar 2026 accounts payables of $11.03M is the 2nd largest of the 3 companies compared; the peer median is $7.34M.
  • Its year-over-year change of -313.0% is the lowest of 3, against a peer median of -31.0%.
  • Accounts payables amounts to 1.4% of revenue for COLL, versus a peer median of 35.6%.
COLL Competitors Peer median
Accounts Payables for COLL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SCLXScilex Holding CompanyLTM Mar 2026$23.68M +109.8%+67.2%69.9%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$11.03M -313.0%—1.4%
PCRXPacira BioSciences, Inc.LTM Mar 2026$9M -171.8%—1.2%
LTGOLatigo Biotherapeutics Inc.—— ———
Peer median (excluding COLL) $7.34M-31.0%+67.2%35.6%

Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income71.52M(25M)48.16M69.19M62.87M
Depreciation & Amortization68.92M138.94M149.26M169.16M220.82M
Deferred Income Tax(78.04M)(8.39M)(2.15M)(26.81M)(25.66M)
Stock-Based Compensation24.26M22.87M27.14M32.4M41.91M
Change in Working Capital13.49M(12.71M)21.73M(54.98M)3.76M
Accounts Receivables(22.52M)(21.78M)3.59M(4.41M)17.2M
Inventory(2.3M)48.27M14.17M13.93M(5.35M)
Accounts Payables(5.83M)(707K)5.06M(11.28M)6.72M
Other Working Capital44.13M(38.5M)(1.09M)(53.21M)(14.81M)
Other Non-Cash Items3.42M8.52M30.62M16.02M25.62M
Operating Cash Flow103.56M124.23M274.75M204.98M329.32M
Capital Expenditures(1.94M)(1.62M)(461K)(1.65M)(1.74M)
Acquisitions (Net)0(572.07M)0(267.54M)0
Purchases of Investments00(92.35M)(111.17M)(126.97M)
Sales of Investments0022M92.6M65.18M
Other Investing Activities00000
Investing Cash Flow(1.94M)(573.69M)(70.81M)(287.76M)(63.53M)
Debt Repayment(50M)442.68M(65.92M)7.52M(70.38M)
Common Stock Issued00005.64M
Common Stock Repurchased(47.86M)(14.06M)(75M)(60.03M)(25.1M)
Dividends Paid00000
Other Financing Activities8.56M8.1M740K(8.1M)(20.4M)
Financing Cash Flow(89.3M)436.72M(140.18M)(60.6M)(110.25M)
Effect of Forex Changes00000
Net Change in Cash12.31M(12.74M)63.76M(143.38M)155.55M
Free Cash Flow101.61M122.61M274.29M203.33M327.58M

Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Intrinsic Alpha fair value

Locked

Current Price

$25.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.